Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05728034 · ClinicalTrials.gov registry record · NA
Information Seeking About Pre-exposure Prophylaxis
A NA study of Pre-exposure Prophylaxis, sponsored by Penn State University.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
- 1
- Study location
NCT05728034: Completed NA study of Pre-exposure Prophylaxis, sponsored by Penn State University.
NCT05728034 is a NA study of Pre-exposure Prophylaxis that has completed, run by Penn State University. The registered enrollment target is 314 participants, above the 167-participant average among 12 other Pre-exposure Prophylaxis trials with a reported enrollment target (88% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05728034, a NA study of Pre-exposure Prophylaxis, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of these two intervention studies is to test promising health communication messaging strategies most likely to enhance Black, Hispanic, and non-Hispanic White YMSM's (young men who have sex with men's) engagement with online content about injectable and oral PrEP (pre-exposure prophylaxis). Participants will be asked to browse a mock Google results page featuring various kinds of PrEP information, and their browsing behavior will be unobtrusively logged. In Study 1, participants will be randomly assigned to browse for information about oral PrEP or browse for information about injectable PrEP. The design of Study 2 will be identical to Study 1 but will focus only on injectable PrEP content. In addition to browsing behavior, visual behavior data will also be collected in Study 2 with eye-trackers.
Primary Outcome
SoSciSurvey software will unobtrusively log the clicks participants will make on the different search results, with each search result reflecting a different messaging strategy (response efficacy, social norms, exemplar, celebrity, and basic information). Our analysis will focus on which search result/messaging strategy participants click on first as a behavioral indicator of message engagement.
Conditions Studied
Interventions
- BEHAVIORAL Injectable PrEP information
- BEHAVIORAL Oral PrEP information
Study Locations (1)
Pennsylvania
- Pennsylvania State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2025-08-18 |
| Phase | NA |
What the finished NCT05728034 record still lists
NCT05728034 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, above the 167-participant average among 12 other Pre-exposure Prophylaxis trials with a reported enrollment target (88% higher).
The record links to 1 condition, with Pre-exposure Prophylaxis appearing as the primary indexed condition, and to 2 interventions - of which Injectable PrEP information is the first listed.
NCT05728034 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05728034 about?
NCT05728034 is a clinical study titled "Information Seeking About Pre-exposure Prophylaxis". The goal of these two intervention studies is to test promising health communication messaging strategies most likely to enhance Black, Hispanic, and non-Hispanic White YMSM's (young men who have sex with men's) engagement with online content about injectable and oral PrEP (pre-exposure prophylaxis)...
What is the current status of trial NCT05728034?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2023-05-30. Estimated completion is 2025-08-18.
What conditions does trial NCT05728034 study?
This clinical trial studies the following conditions: Pre-exposure Prophylaxis.
What interventions are being tested in trial NCT05728034?
The interventions under investigation include: Injectable PrEP information (BEHAVIORAL), Oral PrEP information (BEHAVIORAL).
Who is sponsoring clinical trial NCT05728034?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05728034 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre-exposure Prophylaxis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05728034's enrollment target sits among peer trials
314 3rd of 12 higher than 10 of 12 other Pre-exposure Prophylaxis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pre-exposure Prophylaxis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
RECRUITING · NA
-
Stick2PrEP Cisgender Women and Trans Individuals
RECRUITING · NA
-
Gathering Online for Dialogue and Discussion to Enhance Social Support
RECRUITING · NA
-
Case Management Dyad
RECRUITING · NA
-
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
COMPLETED · NA
-
Optimizing PrEP Adherence for Young Men Who Have Sex With Men
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI